<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99037">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01771458</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2012-04</org_study_id>
    <nct_id>NCT01771458</nct_id>
  </id_info>
  <brief_title>A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer</brief_title>
  <acronym>SHIVA</acronym>
  <official_title>A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHIVA is a proof of concept randomized phase II trial which compares two treatment
      strategies for patients with refractory cancer.

      From a tumor biopsy, a molecular profile of the disease is established (mutations,
      amplifications, hormone receptor status). If a molecular abnormality is identified for which
      an approved targeted agent is available, patients are randomized randomized between two
      arms:

        -  Targeted therapy based on the molecular profile

        -  Conventional therapy based on investigator's choice.

      A cross-over is proposed at disease progression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Patient's progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy.</measure>
    <description>Tumor evaluation according to RECIST 1.1 criteria (every 2 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <description>Tumor evaluation according to RECIST 1.1 criteria (every 2 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatments side effects assessement according to the NCI CTCAE v4.03 scale.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment effect variations as defined by tumor growth according to the altered signaling pathway</measure>
    <description>Evaluation of tumor growth before and during the study (according to RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy after cross-over.</measure>
    <description>Tumor evaluation according to RECIST 1.1 criteria (every 2 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the ability of ctDNA to early predict treament efficacy</measure>
    <description>Comparing treatment efficacy to ctDNA level (before and during treatment course)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the medico-economic impact of the experimental strategy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical feasability of the SHIVA trial: number of screened patient compared to number of patients elligible to randomization.</measure>
    <description>Number of screened patients. Number of patient with a molecular full profil in the timeframe (4 weeks between tumor biopsy and SHIVA's committees decision).
Number of randomized patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Reccurent/Metastatic Solid Tumor Disease</condition>
  <arm_group>
    <arm_group_label>Standard chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment choice is based on Investigator decision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Personalized treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Targeted therapy based on the patient molecular profil (if there is at least one abnormality that could be targeted)
Elligible therapies in this trial are :
Imatinib Everolimus Vemurafenib Sorafenib Erlotinib Lapatinib Trastuzumab Dasatinib Tamoxifen (or letrozole if contra-indication) Abiraterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy based on molecular profiling : Imatinib</intervention_name>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsy</intervention_name>
    <arm_group_label>Standard chemotherapy</arm_group_label>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Chemotherapy</intervention_name>
    <arm_group_label>Standard chemotherapy</arm_group_label>
    <other_name>Based on each investigator choice</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy based on molecular profiling : Everolimus</intervention_name>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy based on molecular profiling : Vemurafenib</intervention_name>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy based on molecular profiling : Sorafenib</intervention_name>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy based on molecular profiling : Erlotinib</intervention_name>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab</intervention_name>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy based on molecular profiling : Dasatinib</intervention_name>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)</intervention_name>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy based on molecular profiling : Abiraterone</intervention_name>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with recurrent/metastatic solid tumor who failed or are not candidate for
             treatments usually proposed in first intentions and for whom a prospective clinical
             trial has been indicated in a tumor board

          2. ECOG performance status of 0 or 1

          3. Biopsiable disease (tumor biopsy mandatory for tumor profiling). The biopsy can be
             performed when patients are being treated with standard therapy for their
             recurrent/metastatic cancer if it is not planned to treat them with molecularly
             targeted agents in the future.

          4. Measurable disease

          5. Adequate renal function defined by a serum creatinine &lt;1.5xUNL (upper normal limit)

          6. Adequate liver function test defined by SGOT &amp; SGPT &lt;3xUNL (5xUNL in case of liver
             metastases), and bilirubin level &lt;1.5xUNL

          7. Adequate bone marrow function defined by platelets &gt;100,000/mm3, hemoglobin &gt;10 g/dL,
             and neutrophils &gt;1,000/mm3

          8. Patients must be affiliated to the French Social Security System

          9. Signed informed consent

         10. For female of child-bearing potential: a negative pregnancy test &lt;72 hours before
             starting study treatment is required. If sexually active, female of childbearing
             potential must use &quot;highly effective&quot; methods of contraception for the study duration
             and for 3 months following the last treatment

         11. For male of reproductive potential: any sexually active male patient must use a
             condom while on study treatment and for 3 months following the last treatment

         12. Agreement to send the CD-ROMs of imaging for central review

        Exclusion Criteria:

          1. Patients who have only bone and/or brain metastases

          2. Patients whose brain metastases have not been controlled for &gt;3 months

          3. Patient participating in another clinical trial with an experimental drug

          4. Patients who are candidate to receive a molecularly targeted agent that is approved
             for their disease

          5. Anticoagulation with anti-vitamin K (Low Molecular Weight Heparin [LMWH] is allowed)

          6. Patients with other concurrent severe and/or uncontrolled medical disease which could
             compromise participation in the study, including uncontrolled diabetes, cardiac
             disease, uncontrolled hypertension, congestive cardiac failure, ventricular
             arrhythmias, active ischemic heart disease, myocardial infection within one year,
             chronic liver or renal disease, active gastrointestinal tract ulceration, severely
             impaired lung function

          7. Pregnant and/or breastfeeding women

          8. Individually deprived of liberty or placed under the authority of a tutor

          9. Patients with any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

         10. Known HIV, HBV, or HCV infection

        Eligibility criteria for the randomized part :

          1. Identification of tumor molecular abnormalities for which the Therapeutic Decision
             Committee (TDC) recommends a molecularly targeted therapy available in the context of
             the trial (even if the molecular profile is incomplete)

          2. Therapy recommended by the TDC is not approved for the patient's disease

          3. ECOG performance status of 0 or 1

          4. Adequate renal function defined by a serum creatinine &lt;1.5xUNL

          5. Adequate liver function tests defined by SGOT &amp; SGPT &lt;3xUNL (5xUNL in case of liver
             metastases), and bilirubin level &lt;1.5xUNL

          6. Adequate bone marrow function defined by platelets &gt;100,000/mm3, hemoglobin &gt;8 g/dL,
             and neutrophils &gt;1,000/mm3

          7. Albumin, LDH and number of metastatic sites have been documented (in order to
             determine the RMH prognostic score)

          8. LVEF &gt;50%

          9. QTc &lt;480 ms on ECG
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe LE TOURNEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia TRESCA, MD</last_name>
    <email>patricia.tresca@curie.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas ISAMBERT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas ISAMBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier TREDAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier TREDAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony GONCALVES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony GONCALVES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Le Tourneau, MD</last_name>
      <phone>+33 1 44 32 44 07</phone>
    </contact>
    <investigator>
      <last_name>Christophe Le Tourneau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital Rene Huguenin</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MITRY, DOCTOR</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuel MITRY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest Centre René Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario CAMPONE, DOCTOR</last_name>
    </contact>
    <investigator>
      <last_name>Mario CAMPONE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre DELORD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre DELORD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Céline GAVOILLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Céline GAVOILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic/Reccurent</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Refractory</keyword>
  <keyword>Molecular profile</keyword>
  <keyword>Targeted treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Imatinib</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
